<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Omega</journal-id><journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id><journal-id journal-id-type="publisher-id">ao</journal-id><journal-id journal-id-type="coden">acsodf</journal-id><journal-title-group><journal-title>ACS Omega</journal-title></journal-title-group><issn pub-type="epub">2470-1343</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7841934</article-id><article-id pub-id-type="doi">10.1021/acsomega.0c05629</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Assessment of the Antileishmanial Potential of <italic>Cassia
fistula</italic> Leaf Extract</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Tabrez</surname><given-names>Shams</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Rahman</surname><given-names>Fazlur</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Ali</surname><given-names>Rahat</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Alouffi</surname><given-names>Abdulaziz S.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Alshehri</surname><given-names>Bader Mohammed</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Alshammari</surname><given-names>Fahdah Ayed</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Alaidarous</surname><given-names>Mohammed A.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Banawas</surname><given-names>Saeed</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Bin Dukhyil</surname><given-names>Abdul Aziz</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><name><surname>Rub</surname><given-names>Abdur</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Infection
and Immunity Lab (414), Department of Biotechnology, <institution>Jamia Millia Islamia (A Central University)</institution>, New Delhi 110025, <country>India</country></aff><aff id="aff2"><label>&#x02021;</label><institution>King
Abdulaziz City for Science and Technology</institution>, P.O. Box 6086, Riyadh 11442, <country>Saudi Arabia</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Medical Laboratory Sciences, College of Applied Medical Sciences, <institution>Majmaah University</institution>, Al Majmaah 11952, <country>Saudi Arabia</country></aff><aff id="aff4"><label>&#x02225;</label>College
of Sciences and Literature Microbiology, <institution>Northern Border University</institution>, P.O. Box 1321, Arar 73222, <country>Saudi Arabia</country></aff><aff id="aff5"><label>&#x022a5;</label>Health
and Basic Sciences Research Center, <institution>Majmaah
University</institution>, Al Majmaah 15341, <country>Saudi Arabia</country></aff><aff id="aff6"><label>#</label>Department
of Biomedical Sciences, <institution>Oregon State University</institution>, Corvallis, Oregon 97331, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>arub@jmi.ac.in</email>. Tel: <phone>+91-9560887383</phone>.</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>01</month><year>2021</year></pub-date><pub-date pub-type="collection"><day>26</day><month>01</month><year>2021</year></pub-date><volume>6</volume><issue>3</issue><fpage>2318</fpage><lpage>2327</lpage><history><date date-type="received"><day>18</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The
Authors. Published by American
Chemical Society</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Authors</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0008" id="ab-tgr1"/></p><p><italic>Cassia
fistula</italic> has a wide array
of biologically active and therapeutically important class of compounds. <italic>Leishmania donovani</italic> important drug targets, sterol
24-c methyltransferase (<italic>Ld</italic>SMT), trypanothione reductase
(<italic>Ld</italic>TR), pteridine reductase (<italic>Ld</italic>PTR1),
and nucleoside hydrolase (<italic>Ld</italic>NH), were modelled, and
molecular docking was performed against the abundant phytochemicals
of its leaf extract. Molecular docking results provided the significant
prima facie evidence of the leaf extract to have antileishmanial potential.
To confirm this, we performed <italic>in vitro</italic> antileishmanial
and cytotoxicity assays. Methanolic extract of <italic>C. fistula</italic> leaves showed growth inhibition and proliferation of <italic>L. donovani</italic> promastigote with an IC<sub>50</sub> value
of 43.31 &#x000b1; 4.202 &#x003bc;g/mL. It also inhibited the growth of
intra-macrophagic amastigotes with an IC<sub>50</sub> value of 80.76
&#x000b1; 3.626 &#x003bc;g/mL. <italic>C. fistula</italic> extract was found cytotoxic at a very high concentration on human
macrophages (CC<sub>50</sub> = 626 &#x000b1; 39 &#x003bc;g/mL). Annexin
V/propidium iodide (PI) staining assay suggested partial apoptosis
induction in parasites by <italic>C. fistula</italic> to exert its antileishmanial activity. Here, for the first time,
we have shown the antileishmanial potential of <italic>C. fistula</italic> leaves. Overall, our results could open new insight for an affordable
and natural antileishmanial with high efficacy and less toxicity.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ao0c05629</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ao0c05629</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Leishmaniasis is a vector-borne complex parasitic disease caused
by obligate intramacrophagic protozoan parasite <italic>Leishmania</italic>. Leishmaniasis is a major global health problem threatening almost
350 million people worldwide with about 1.2&#x02013;2 million new cases
reported annually.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Leishmaniasis is manifested
in three clinical forms: visceral, mucocutaneous, and cutaneous; the
visceral form is the severest with approximately 500&#x0202f;000 new
cases reported annually.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Visceral leishmaniasis
(VL) or kala azar, is a lethal, chronic neglected tropical disease
caused by intracellular protozoan parasites <italic>Leishmania
infantum</italic> and <italic>Leishmania donovani</italic>. VL is endemic in more than 80 countries; however, about 80% of
new VL cases worldwide are reported from the Indian subcontinent (India,
Nepal, and Bangladesh).<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> If left untreated,
VL becomes fatal. There is no vaccine available for human leishmaniasis.
Currently, VL is treated using leishmanicidal drugs such as paromomycin,
amphotericin B, liposomal amphotericin (AmBisome), and only available
oral drug miltefosine (MIL).<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Initially,
these drugs had shown promising efficacy, but current studies have
reported relapse rates between 6.8 and 10.8% after 6 months post-chemotherapeutics
in immunocompetent patients in India.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> The higher
pathogenicity of <italic>L. donovani</italic> was connected
with both SSG treatment failure and relapse after MIL treatment.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Drug resistance is another complication associated
with the available chemotherapeutics. In addition, the available drugs
have limitations like high cost, least availability, toxicity, and
painful route of administration. Therefore, there is a need for new
therapeutic options. Plants and their constituents had been in use
for primary health care since ancient times. <italic>Cassia
fistula</italic> Linn belongs to the family Caesalpiniaceae
usually known as Amulthus and has been broadly used for the treatment
and prevention of diseases in different types of traditional medicines.
It is also known as the golden shower and Indian laburnum.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup><italic>C. fistula</italic> is
a very common plant known for its various medicinal properties and
is native to South Asia and grown in other parts of the world. Animal
model-based studies have shown that <italic>C. fistula</italic> and their constituents play a role in disease management via modulation
of biological activities.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup><italic>C. fistula</italic> has been reported to have antifertility,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> antipyretic, analgesic, anti-inflammatory, hypoglycemic
effects, and antimicrobial activity.<sup><xref ref-type="bibr" rid="ref10">10</xref>&#x02212;<xref ref-type="bibr" rid="ref14">14</xref></sup></p><p>In the current study, first, we searched the
literature for the
mention of the chemical constituents of <italic>C. fistula</italic> leaf extracts through mass spectrometry techniques. There are around
12 different major molecules in the leaf extract of <italic>C. fistula.</italic>(<xref ref-type="bibr" rid="ref15">15</xref>) Most of
these phytoconstituents are flavonoids, and many of them have medicinal
values including antimicrobial activities.<sup><xref ref-type="bibr" rid="ref10">10</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup><italic>p</italic>-Coumaric acid is a phenolic acid of the hydroxycinnamic
acid family that shows <italic>in vitro</italic> antiviral activity
against hepatitis C virus at the initial stage and antileishmanial
activity.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref></sup> Syringaresinol is a furofuran-type lignin
and shows antileishmanial activity.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Myricetin
belongs to the flavonoid class of polyphenolic compounds that possesses
antioxidant and is known for its nutraceutical values.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Myricetin exhibits antibacterial activity against
Gram-negative bacteria and antiviral activity, acting as a strong
inhibitor of reverse transcription of human immunodeficiency virus
(HIV) and Rauscher murine leukemia virus (RLV).<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Proanthocyanidins, recognized as condensed tannins, are
a class of flavonoids present as an active compound in medicinal plants
and occur as polymers of different oligomeric forms.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Furthermore, proanthocyanidins are known for their antibacterial,
antiviral, and antileishmanial activities.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> It has been reported that flavonoids are a potential candidate for
leishmanicidal drugs.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup><italic>L. donovani</italic> contain many significant enzymes, which
are considered as potential drug targets for the development of new
therapeutic molecules. We have selected four key drug targets of <italic>L. donovani</italic> for molecular docking studies against
the abundant phytochemicals of leaf extract. <italic>Ld</italic>PTR1
is an NADPH-dependent short-chain reductase responsible for the retrieval
of pterins in the protozoan parasite <italic>Leishmania</italic>. This enzyme acts as a metabolic bypass for drugs targeting dihydrofolate
reductase.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The <italic>Ld</italic>TR
enzyme follows thiol-redox metabolism to keep trypanothione in its
reduced form. This antioxidant property of <italic>Ld</italic>TR is
essential for the survival of <italic>L. donovani.</italic>(<xref ref-type="bibr" rid="ref23">23</xref>)<italic>Ld</italic>SMT is required
for the biosynthesis of ergosterol, the major membrane sterol in <italic>L. donovani</italic>, responsible for parasite virulence,
and highly conserved protein among <italic>Leishmania</italic> species.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref25">25</xref></sup><italic>Ld</italic>NH are conserved phylogenetic markers and important
enzymes for the replication of DNA of the parasites.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> We have selected these enzymes for molecular docking with
major constituents of <italic>C. fistula</italic> for
predicting the possible antileishmanial activity of these molecules.
In silico approaches have been effectively used to predict protein
structures and protein&#x02013;ligand interactions. Molecular docking
is a computational method used to speculate the preferred orientation
of ligands (organic molecules) with the proteins. Accordingly, nature
provides a huge diversity and an alternative source of valuable chemical
structures for biological screening test against pathogens. We further
tested our hypothesis through different antileishmanial and cytotoxicity
assays on promastigotes, amastigotes, and human THP-1-derived macrophages.</p></sec><sec id="sec2"><label>2</label><title>Material and Methods</title><sec id="sec2.1"><label>2.1</label><title>Molecular Docking Studies</title><p>PyRx was
used for the virtual screening of the phytochemical compounds and
target proteins of <italic>L. donovani</italic>.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The target protein was changed into a macromolecule,
which converted the atomic coordinates into pdbqt format. The grid
box was selected around the crystal structure while other parameters
were left as default for molecular docking by AutoDock Vina.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The binding affinity and inhibitory constant
were used to analyze the results of molecular docking, and then all
possible docked conformations were generated for different constituents.
The detailed interactions, including their types such as hydrogen
bonding, van der Waals, alkyl, pi-alkyl, and halogen interactions,
between different constituents and the target proteins were analyzed
by BIOVIA Discovery Studio.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The most
favorable binding poses of the compounds were analyzed by choosing
the lowest free energy of binding (&#x00394;<italic>G</italic>) and
the lowest inhibition constant (<italic>K</italic>i), which is calculated
using the following formula:<disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_m001" position="anchor"/></disp-formula>where &#x00394;<italic>G</italic> is the binding
affinity (kcal/mol), <italic>R</italic> (gas constant) is 1.98 cal
K<sup>&#x02013;1</sup> mol<sup>&#x02013;1</sup>, and <italic>T</italic> (room temperature) is 298.15 Kelvin.</p></sec><sec id="sec2.2"><label>2.2</label><title>Sequence
Analysis, Template Identification,
Homology Modeling, Receptor and Ligand Preparation</title><p>Due to
the lack of solved three-dimensional (3D) structures of <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>SMT, homology modeling
was opted to determine the structure of these enzymes. The protein
sequence of <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>SMT enzymes of <italic>L. donovani</italic> was retrieved from NCBI. For the identification of similar templates,
BlastP<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> was performed against Protein
Data Bank (PDB), and on the basis of maximum sequence similarity and
least <italic>e</italic>-value, the crystal structures were used as
template structures to model the 3D structures. Modeller 9.24<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> was used for homology modeling, and 3D structures
were visualized in PyMol. The generated models were assessed by the
PROCHECK program, PDB sum tool, and Ramachandran plots.<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> The crystal structure of pteridine reductase protein was downloaded
from PDB (ID: 2XOX). The proteins were finally prepared by Discovery Studio keeping
all of the parameters at default. The critical residues of the binding
pockets were identified from the native catalytic pockets of the available
crystal structure of proteins, CASTp, and Discovery Studio. The 3D
structure of the constituents of the leaf extract of <italic>C. fistula</italic> was retrieved from the PubChem database
in SDF format.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Syringaresinol, quercetin-<italic>O</italic>-hexoside, and apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside were sketched by MarvinSketch. The atomic coordinates
of all of the ligands were changed to pdbqt setup using Open Babel
GUI, an open-source chemical toolbox for the interconversion of chemical
structures.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Universal Force Field (uff)
was used for energy minimization.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup></p></sec><sec id="sec2.3"><label>2.3</label><title>Chemicals and Reagents</title><p>M199 media
for promastigote culturing, Roswell Park Memorial Institute (RPMI)
1640 media for the cell line, penicillin&#x02013;streptomycin antibiotic
cocktail, and fetal bovine serum (FBS) were procured from Gibco and
Thermo Fisher Scientific, Inc., Waltham, MA. <italic>N</italic>-2-hydroxyethylpiperazine-<italic>N</italic>&#x02019;-2-ethanesulfonic acid (HEPES), sodium bicarbonate,
paraformaldehyde were obtained from Sigma-Aldrich, Saint Louis, MO.
Miltefosine, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium
bromide (MTT) assay reagents, and cell culture-grade dimethyl sulfoxide
(DMSO) and other solvents for plant extract were from Merck &#x00026;
Co., Inc., Kenilworth, NJ. Propidium iodide and Annexin fluorescein
isothiocyante (FITC) was procured from Thermo Fisher Scientific, Inc.,
Waltham, MA. All of the other chemicals and reagents were purchased
from Sigma-Aldrich, Saint Louis, MO, or Merck &#x00026; Co., Inc., Kenilworth,
NJ, unless stated otherwise.</p></sec><sec id="sec2.4"><label>2.4</label><title>Promastigote Phase Parasites
and THP-1 Cell
Line Culture and Maintenance</title><p><italic>L. donovani</italic> infective strain (MHOM/IN/83/AG83) was maintained in M199 media
at pH 7.4 supplemented with 25 mM HEPES, 10% heat-inactivated FBS,
and 1% penicillin&#x02013;streptomycin antibiotic cocktail at a temperature
of 22 &#x000b0;C. The log-phase parasite culture was passaged at regular
intervals of 72&#x02013;96 h with an inoculum density of 2 &#x000d7; 10<sup>6</sup> parasites per mL. THP-1 human monocytic cell line was maintained
in RPMI-1640 media supplemented with 10% FBS and 1% penicillin&#x02013;streptomycin
antibiotic in a humidified atmosphere in a CO<sub>2</sub> incubator
at 5% CO<sub>2</sub> and 37 &#x000b0;C temperature. THP-1 monocytic cells
were stimulated with 20 ng/mL of phorbol myristate acetate (PMA) for
differentiation to macrophages.</p></sec><sec id="sec2.5"><label>2.5</label><title>Plant
Extract Preparation</title><p><italic>C. fistula</italic> leaves were collected from natural habitats,
and the identification was done by Dr. Sunita Garg, Chief Scientist
and Head, Herbarium Department, National Institute of Science Communication
and Information Resources (NISCAIR), New Delhi, India (ref No. NISCAIR/RHMD/Consult/2018/3268-69-5).
After collecting it from the field, selected plant materials were
washed and air-dried in shade at room temperature. After the leaves
were moisture-free, they were grounded separately in an electric grinder.
The prepared powder form of plant materials (100 g) was soaked in
500 mL of methanol and placed on a rotary shaker at room temperature
for 24 h. The extract was filtered using a Buchner funnel and Whatman
filter paper and concentrated to dryness using a rotary evaporator
under vacuum at 35 &#x000b0;C. The dried plant extract was stored at
&#x02212;20 &#x000b0;C until used for bioassay.</p></sec><sec id="sec2.6"><label>2.6</label><title>IC<sub>50</sub> Determination of <italic>C. fistula</italic> Leaf Extract</title><p>To check the antipromastigote
activity of <italic>C. fistula</italic>, log-phase promastigotes
were incubated at a density of 5 &#x000d7; 10<sup>6</sup> parasites in
the presence and absence of leaf methanolic extract. To determine
the IC<sub>50</sub> value, parasites were incubated at different concentrations
of extract. The percentage inhibition was calculated as (mean parasite
number of treated sample/mean parasite of control) &#x000d7; 100. The
IC<sub>50</sub> value was determined by extrapolating the graph of
% of viable parasites under treatment versus the concentration of
extract.</p></sec><sec id="sec2.7"><label>2.7</label><title>Antiamastigote Assay and Cytotoxicity Evaluation
of <italic>C. fistula</italic> Extract</title><p>Treatment
of 2 &#x000d7; 10<sup>6</sup> differentiated macrophages with twofold
serial dilution of extract was conducted for 24 h. Cells were incubated
with 50 &#x003bc;M MTT for 3&#x02013;4 h; thereafter, the resulting formazan
was dissolved in 150 &#x003bc;M DMSO. The amount of formazan produced
represented the relative number of viable cells and was recorded spectrophotometrically
at 570 nm by an ELISA plate reader. The CC<sub>50</sub> value (50%
cell cytotoxic concentration) was defined by the graphical extrapolation
of the dose&#x02013;response curve of % viability against the plant
extraction concentration. For parasite load study, 2 &#x000d7; 10<sup>5</sup> THP-1 cells were seeded on the coverslip, and after proper
differentiation to macrophages using PMA, the adherent cells were
infected with log-phase virulent promastigotes in a ratio of 1:10
(macrophage to <italic>Leishmania</italic>) for 24 h.
The noninternalized parasites were washed, and the infected macrophages
were further incubated with different concentrations of plant extract,
for the next 24 h. The coverslips were washed, fixed with chilled
methanol, and stained using a modified Giemsa stain for microscopic
observation of amastigotes. About 100 macrophages were counted from
different focus to determine the parasite burden.</p></sec><sec id="sec2.8"><label>2.8</label><title>Apoptotic Assay</title><p><italic>L.
donovani</italic> promastigotes (2 &#x000d7; 10<sup>6</sup>) were
incubated at different doses of plant extract (31.7, 62.5, and 125
&#x003bc;g/mL) and incubated for 48 h. Miltefosine at a dose of 3 &#x003bc;g/mL
served as positive control, and parasites without treatment were considered
as a negative control. Treated and untreated promastigotes were further
centrifuged at 3000<italic>g</italic> for 5 min and washed three times
in 1&#x000d7; PBS buffer. Further, the pellet was resuspended in 195
&#x003bc;L of 1&#x000d7; binding buffer (10 mM Hepes (pH 7.4), 140 mM NaCl,
and 2.5 mM CaCl<sub>2</sub>) containing 5 &#x003bc;L of annexin-FITC
and 5 &#x003bc;L of propidium iodide for 25 min in the dark at room
temperature in a dark room. After 25 min of incubation, the samples
were analyzed through a BD FACSAria III Cell Sorter at excitation
wavelengths of 488 and 550 nm.</p></sec><sec id="sec2.9"><label>2.9</label><title>Statistical
Analysis</title><p>All of the experiments
were performed in technical triplicate, and the results represented
are the mean of the triplicate with scanning electron microscopy (SEM).
Statistical analysis was performed using GraphPad Prism 7.0 software,
and the statistical significance was calculated using one-way analysis
of variance (ANOVA) followed by Dunnett&#x02019;s multiple comparison
test. <italic>P</italic> &#x0003c; 0.5 was considered statistically significant.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Homology Modeling and Molecular
Docking</title><p>The <italic>Ld</italic>SMT, <italic>Ld</italic>TR,
and <italic>Ld</italic>NH drug targets were modeled using Modeller
9.24 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c05629/suppl_file/ao0c05629_si_001.pdf">Table S1</ext-link>). The best model among the
hundred generated
models was chosen based on the lowest score for the docking study.
The energy minimization was carried out by the BIOVIA Discovery Studio.
The three-dimensional cartoon representations of <italic>Ld</italic>SMT, <italic>Ld</italic>TR, and <italic>Ld</italic>NH are shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c05629/suppl_file/ao0c05629_si_001.pdf">Figures S1A&#x02013;S3A</ext-link>, respectively. The generated
models of <italic>Ld</italic>SMT, <italic>Ld</italic>TR, and <italic>Ld</italic>NH show stereochemical quality having 99.8, 100.0, and
99.0% residues in allowed regions and only 0.2, 0.0, and 1.0% residues
in disallowed region of Ramachandran plot, respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c05629/suppl_file/ao0c05629_si_001.pdf">Figures S1B&#x02013;D, S2B&#x02013;D, and S3B&#x02013;D</ext-link>). CASTp and Discovery Studio were used to find the key residues
and region around the binding cavity of <italic>Ld</italic>SMT, <italic>Ld</italic>TR, and <italic>Ld</italic>NH. The active-site residues
of the <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1 enzymes making different numbers
of hydrogen bonds within 3.5 &#x000c5; as well as hydrophobic bonds within
5 &#x000c5; of the ligands were identified. Among all kinds of various
interactions like amide&#x02212;&#x003c0; interactions, &#x003c0;&#x02013;&#x003c0;,
H-bond, etc., the binding efficiency is being evaluated on the idea
of hydrogen bonding.<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> Virtual screening was performed
against active-site residues of <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1 targets using
PyRx. After the successful screening of the phytochemicals present
in the methanolic leaf extract of <italic>C. fistula</italic>, the top ligands with the lowest binding energy were selected. Based
on binding energy and inhibitory constant, six complexes having the
highest binding affinities were carefully chosen for further analysis
(<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Proanthocyanidin
B dimer has been found to possess the lowest binding energy and the
highest binding affinity ranging from &#x02212;9.4 to &#x02212;6.8 kcal/mol
against <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1 enzymes, as shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. The binding pattern of the
proanthocyanidin B dimer with <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1 may hinder
the substrate accessibility and its subsequent inhibition, as shown
in <xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref>&#x02013;<xref rid="fig4" ref-type="fig">4</xref> A. Proanthocyanidin
B dimer interacts with the Asp168, Thr170, Phe264, Glu265, and Ile272
binding-site residues of <italic>Ld</italic>SMT by five intermolecular
hydrogen bonds with bond lengths of 2.65, 2.80, 2.78, 2.19, 2.62,
and 3.61 &#x000c5;, respectively (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A). Proanthocyanidin B dimer interacts with the <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1
enzymes by four, two, and one hydrogen bonds having bond lengths of
2.18, 2.20, 2.51, and 2.58; 2.13 and 2.77; and 2.39 &#x000c5;, respectively,
as represented in <xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>&#x02013;<xref rid="fig4" ref-type="fig">4</xref>A. Kaempferol rhamnosylxyloside
has shown the second-highest binding energy between &#x02212;9.3 and
&#x02212;6.5 kcal/mol against the targeted enzymes (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Kaempferol rhamnosylxyloside
interacts with the Met237(2), Glu238(2), Leu297, Thr298(2), and Arg309
residues of <italic>Ld</italic>SMT by eight intermolecular hydrogen
bonds having bond lengths of 2.07, 2.11, 2.22, 3.02, 2.74, 2.08, 2.74,
and 2.85 &#x000c5;, respectively (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). Kaempferol rhamnosylxyloside interacts with <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1
through four, three, and two hydrogen bonds having bond lengths of
2.48, 2.69, 2.34, and 2.31; 2.55, 2.72, and 2.67; and 2.70 and 2.77
&#x000c5;, respectively, as shown in <xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>B, <xref rid="fig3" ref-type="fig">3</xref>D, and <xref rid="fig4" ref-type="fig">4</xref>C. The Asn163, Met164, Cys189, Val193, and Ile258
residues of <italic>Ld</italic>SMT interact with Myricetin hexoside
by five intermolecular hydrogen bonds having bond lengths of 2.08,
1.97, 2.97, 2.06, and 2.44 &#x000c5;, respectively (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C). Apigenin-6,8-di-<italic>C</italic>-glycoside interacts with <italic>Ld</italic>SMT through
four hydrogen bonds with bond lengths of 2.92, 2.24, 2.40, and 2.89
&#x000c5;, as shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D. Myricetin hexoside interacts with <italic>Ld</italic>TR
through five hydrogen bonds with bond lengths of 2.29, 2.60, 2.92,
2.22, and 2.95 &#x000c5;, as shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C. Apigenin-6,8-di-<italic>C</italic>-glycoside
interacts with the Asp160, Asn163, Met164, and Val193 residues of <italic>Ld</italic>SMT by eight intermolecular hydrogen bonds having bond
lengths of 2.92, 2.24, 2.40, and 2.89 &#x000c5;, respectively (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D). Apigenin-C-hexoside-O-pentoside
interacts with <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1 by three, seven, and two intermolecular hydrogen
bonds having bond lengths of 2.86, 2.01, and 2.88; 2.15, 1.98, 2.25,
2.19, 2.91, 2.23, and 2.70; and 3.08 and 1.94 &#x000c5;, respectively
(<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig">2</xref></xref>D, <xref rid="fig3" ref-type="fig">3</xref>B, and <xref rid="fig4" ref-type="fig">4</xref>D). 3,4-Di-<italic>O</italic>-caffeoylquinic acid interacts with <italic>Ld</italic>NH and <italic>Ld</italic>PTR1 by five and six intermolecular hydrogen
bonds having bond lengths of 3.10, 1.99, 2.68, 2.52, and 2.87; and
2.49. 2.46, 1.96, 2.59, 2.15, and 1.77 &#x000c5; respectively (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>C and <xref rid="fig4" ref-type="fig">4</xref>B).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Binding pattern of <italic>C. fistula</italic> major
chemical constituents with the SMT of <italic>L. donovani</italic>. Two-dimensional (2D) plot, surface representation of protein binding
pocket residues, and its significant interactions with (A) proanthocyanidin
B dimer, (B) kaempferol rhamnosylxyloside, (C) myricetin hexoside,
and (D) apigenin-6,8-di-<italic>C</italic>-glycoside.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0002" id="gr1" position="float"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Binding pattern of <italic>C. fistula</italic> major
chemical constituents with the TR of <italic>L. donovani</italic>. 2D plot, surface representation of protein binding pocket residues,
and its significant interactions with (A) proanthocyanidin B dimer,
(B) kaempferol rhamnosylxyloside, (C) myricetin hexoside, and (D)
apigenin-6-<italic>C</italic>-glucoside 8-<italic>C</italic>-arabinoside.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0003" id="gr2" position="float"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Binding pattern of <italic>C. fistula</italic> major
chemical constituents with the NH of <italic>L. donovani</italic>. 2D plot, surface representation of protein binding pocket residues,
and its significant interactions with (A) proanthocyanidin B dimer,
(B) apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside,
(C) 3,4-di-<italic>O</italic>-caffeoylquinic acid, and (D) kaempferol
rhamnosylxyloside.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0004" id="gr3" position="float"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Binding pattern of <italic>C. fistula</italic> major
chemical constituents with the PTR1 of <italic>L. donovani</italic>. 2D plot, surface representation of protein binding pocket residues,
and its significant interactions with (A) proanthocyanidin B dimer,
(B) 3,4-di-<italic>O</italic>-caffeoylquinic acid, (C) kaempferol
rhamnosylxyloside, and (D) apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0005" id="gr4" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Molecular
Docking Interaction of Abundant
Medicinal Phytochemicals in the Liquid Chromatography&#x02013;Mass
Spectrometry (LC&#x02013;MS) Analysis Data of <italic>C. fistula</italic> with the <italic>L. donovani</italic> Drug Target
Proteins<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">s. no.</th><th style="border:none;" align="center">proteins</th><th style="border:none;" align="center">ligands</th><th style="border:none;" align="center" char=".">binding energy (kcal/mol)</th><th style="border:none;" align="center" char=".">p<italic>K</italic>i<sub>pred</sub> (&#x003bc;M)</th><th style="border:none;" align="center" char=".">no. of H-bonds</th><th style="border:none;" align="center">interacting residues</th></tr></thead><tbody><tr><td rowspan="4" style="border:none;" align="left">1.</td><td rowspan="4" style="border:none;" align="left">sterol 24-<italic>C</italic>-methyltransferase</td><td style="border:none;" align="left">proanthocyanidin B dimer</td><td style="border:none;" align="char" char=".">&#x02013;9.4</td><td style="border:none;" align="char" char=".">6.92</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="left">Asp168,&#x000a0;Thr170,&#x000a0;Phe264,&#x000a0;Glu265,&#x000a0;Ile272</td></tr><tr><td style="border:none;" align="left">kaempferol
rhamnosylxyloside</td><td style="border:none;" align="char" char=".">&#x02013;9.3</td><td style="border:none;" align="char" char=".">6.84</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="left">Met237(2),&#x000a0;Glu238(2),&#x000a0;Leu297,&#x000a0;Thr298(2),&#x000a0;Arg309</td></tr><tr><td style="border:none;" align="left">myricetin
hexoside</td><td style="border:none;" align="char" char=".">&#x02013;9.0</td><td style="border:none;" align="char" char=".">6.62</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="left">Asn163,&#x000a0;Met164,&#x000a0;Cys189,&#x000a0;Val193,&#x000a0;Ile258</td></tr><tr><td style="border:none;" align="left">apigenin-6,8-di-<italic>C</italic>-glycoside</td><td style="border:none;" align="char" char=".">&#x02013;8.9</td><td style="border:none;" align="char" char=".">6.55</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="left">Asp160,&#x000a0;Asn163,&#x000a0;Met164,&#x000a0;Val193</td></tr><tr><td rowspan="4" style="border:none;" align="left">2.</td><td rowspan="4" style="border:none;" align="left">trypanothione reductase</td><td style="border:none;" align="left">proanthocyanidin B dimer</td><td style="border:none;" align="char" char=".">&#x02013;8.4</td><td style="border:none;" align="char" char=".">6.18</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="left">Met70,&#x000a0;Leu88(2),&#x000a0;Ser87</td></tr><tr><td style="border:none;" align="left">kaempferol rhamnosylxyloside</td><td style="border:none;" align="char" char=".">&#x02013;8.2</td><td style="border:none;" align="char" char=".">6.03</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="left">Gly229,&#x000a0;Met333,&#x000a0;Val362,&#x000a0;Gly376</td></tr><tr><td style="border:none;" align="left">myricetin hexoside</td><td style="border:none;" align="char" char=".">&#x02013;7.7</td><td style="border:none;" align="char" char=".">5.66</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="left">His359,&#x000a0;Gly376,&#x000a0;Thr378,&#x000a0;Glu381(2)</td></tr><tr><td style="border:none;" align="left">apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside</td><td style="border:none;" align="char" char=".">&#x02013;7.7</td><td style="border:none;" align="char" char=".">5.66</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="left">Thr374,&#x000a0;Gly376(2)</td></tr><tr><td rowspan="4" style="border:none;" align="left">3.</td><td rowspan="4" style="border:none;" align="left">nucleoside
hydrolase</td><td style="border:none;" align="left">proanthocyanidin B dimer</td><td style="border:none;" align="char" char=".">&#x02013;7.8</td><td style="border:none;" align="char" char=".">5.74</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="left">Asn160,&#x000a0;Thr238</td></tr><tr><td style="border:none;" align="left">apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside</td><td style="border:none;" align="char" char=".">&#x02013;7.7</td><td style="border:none;" align="char" char=".">5.66</td><td style="border:none;" align="char" char=".">7</td><td style="border:none;" align="left">Thr158,&#x000a0;Gly159,&#x000a0;Asp192,&#x000a0;His195(2),&#x000a0;Gln196,&#x000a0;Arg233</td></tr><tr><td style="border:none;" align="left">3,4-di-<italic>O</italic>-caffeoylquinic acid</td><td style="border:none;" align="char" char=".">&#x02013;7.6</td><td style="border:none;" align="char" char=".">5.59</td><td style="border:none;" align="char" char=".">5</td><td style="border:none;" align="left">His157,&#x000a0;Thr158,&#x000a0;Asp192,&#x000a0;Arg233(2)</td></tr><tr><td style="border:none;" align="left">kaempferol
rhamnosylxyloside</td><td style="border:none;" align="char" char=".">&#x02013;7.5</td><td style="border:none;" align="char" char=".">5.52</td><td style="border:none;" align="char" char=".">3</td><td style="border:none;" align="left">Asp192,&#x000a0;His195,&#x000a0;Arg233</td></tr><tr><td rowspan="4" style="border:none;" align="left">4.</td><td rowspan="4" style="border:none;" align="left">pteridine reductase</td><td style="border:none;" align="left">proanthocyanidin B dimer</td><td style="border:none;" align="char" char=".">&#x02013;6.8</td><td style="border:none;" align="char" char=".">5.00</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="left">Glu256</td></tr><tr><td style="border:none;" align="left">3,4-di-<italic>O</italic>-caffeoylquinic acid</td><td style="border:none;" align="char" char=".">&#x02013;6.8</td><td style="border:none;" align="char" char=".">5.00</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="left">Val180,&#x000a0;Tyr194,&#x000a0;Lys198(2),&#x000a0;Pro224,&#x000a0;Asp280</td></tr><tr><td style="border:none;" align="left">kaempferol rhamnosylxyloside</td><td style="border:none;" align="char" char=".">&#x02013;6.5</td><td style="border:none;" align="char" char=".">4.78</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="left">Val279,&#x000a0;Asp280</td></tr><tr><td style="border:none;" align="left">apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside</td><td style="border:none;" align="char" char=".">&#x02013;6.1</td><td style="border:none;" align="char" char=".">4.49</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="left">Val180,&#x000a0;Glu256</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Abbreviations:
p<italic>K</italic>i, negative decimal logarithm of inhibition constant;
pred, predicted.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.2"><label>3.2</label><title><italic>C. fistula</italic> Leaf
Extract Inhibited the Growth of <italic>L. donovani</italic></title><p>It was found that <italic>C. fistula</italic> treatment reduced the promastigote proliferation in a time- and
dose-dependent manner. The IC<sub>50</sub> value of <italic>C. fistula</italic> leaf methanolic extract was determined
by incubating the parasites at different concentrations including
250, 125, 62.5, 31.25, 15.62, 7.81, and 3.90 &#x003bc;g/mL. By extrapolating
the dose&#x02013;response curve, the IC<sub>50</sub> value was found
to be 43.31 &#x000b1; 4.202 &#x003bc;g/mL (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>B).</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Antileishmanial activity of <italic>C.
fistula</italic> leaf extract: (A) THP-1-differentiated macrophages
were treated
with different concentrations of <italic>C. fistula</italic> and miltefosine (0&#x02013;1000 &#x003bc;g/mL) and cell viability was
ascertained by MTT assay. (B) 5 &#x000d7; 10<sup>6</sup> stationary phase <italic>L. donovani</italic> promastigotes were treated with different
concentrations of <italic>C. fistula</italic> leaf methanolic
extracts, with miltefosine-treated positive control and untreated
control. Each set is statistically significant compared to control.
(C) THP-1-differentiated macrophages were parasitized in a 1:10 ratio
with stationary phase promastigotes and then treated with different
concentrations of <italic>C. fistula</italic> leaf extract.
Percent reduction in the parasite load was determined as described
in the method. (D) Intramacrophagic parasites were stained with modified
Giemsa stain. The images were captured at 100X under oil immersion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0006" id="gr5" position="float"/></fig></sec><sec id="sec3.3"><label>3.3</label><title>Cytotoxicity Evaluation
of <italic>C. fistula</italic> Leaf Extract</title><p>To evaluate the
cytotoxic effect of <italic>C. fistula</italic> leaf
methanolic extract, THP-1 differentiated macrophages were incubated
at twofold serial dilution (0&#x02013;1000 &#x003bc;g/mL), and the viability
was assessed by the MTT assay. <italic>C. fistula</italic> was found safe and least cytotoxic on human macrophages with a CC<sub>50</sub> of 626 &#x000b1; 39 &#x003bc;g/mL, while the standard available
control drug miltefosine has a CC<sub>50</sub> value of 7.133 &#x000b1;
0.65 &#x003bc;g/mL (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>A).</p></sec><sec id="sec3.4"><label>3.4</label><title>Effect of <italic>C. fistula</italic> Leaf Extract on the Intramacrophagic Parasites</title><p>After infection, <italic>L. donovani</italic> parasites
internalize inside macrophages
and transform into amastigotes form. These amastigotes are nonmotile
and define the parasite pathogenicity. These amastigote phase parasites
are in the clinically relevant form, so it is important to check the
effect of <italic>C. fistula</italic> extract on them.
THP-1 differentiated macrophages were infected by <italic>L.
donovani</italic> promastigotes for 24 h and then treated with
different doses of the extract. The extract showed a dose-dependent
reduction in parasite burden with an IC<sub>50</sub> value of 80.76
&#x000b1; 3.626 &#x003bc;g/mL (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>C). Miltefosine was taken as a positive control. A
significant reduction in the amastigote count was observed in the
micrographs of infected but extract-treated macrophages (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>D).</p></sec><sec id="sec3.5"><label>3.5</label><title><italic>C. fistula</italic> Leaf
Extract Induced Apoptosis in Parasites <italic>In Vitro</italic></title><p>Further, to evaluate whether <italic>C. fistula</italic>-mediated antileishmanial activity was based on apoptosis induction
in parasites, we performed the annexin V/PI apoptosis assay. Parasites
were treated with different concentrations of methanolic leaf extract
for 48 h and then stained and analyzed through a flow cytometer. At
62.5 &#x003bc;g/mL concentration of extract, 8.2% of parasites were
found in the early apoptotic phase and 14.3% in the late apoptotic
phase (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). At
125 &#x003bc;g/mL treatment, there were 5.1% cells in the early apoptotic
phase and 16.6% cells in the late apoptotic phase (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>). Plant extract induced apoptosis
in parasites in a dose-dependent manner. It is also observed that
shifting from early to late apoptotic was in a dose-dependent manner.
This result suggested that <italic>C. fistula</italic> exerts antileishmanial activity partially through the induction
of apoptosis in parasites.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Proapoptotic evaluation of <italic>C.
fistula</italic> methanolic extract: <italic>L. donovani</italic> promastigotes
were treated with different concentrations of <italic>C. fistula</italic> leaf extract and miltefosine for 48 h and dual-stained with FITC-Annexin
V and PI. The bottom left quadrant represents the live parasites,
top left PI-stained&#x02014;necrotic, and bottom right represents the
early apoptotic and the top right late apoptotic parasites.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_0007" id="gr6" position="float"/></fig></sec></sec><sec id="sec4"><label>4</label><title>Discussions</title><p>Plants
extracts have promising medicinal properties and had been
used in the traditional system of medicine. The available ethnopharmacological
data of different identified medicinal plants and their secondary
metabolites have enormous potential for the discovery of cost-effective,
low cytotoxic, and potential antileishmanial drugs.<sup><xref ref-type="bibr" rid="ref39">39</xref>&#x02212;<xref ref-type="bibr" rid="ref41">41</xref></sup> The <italic>C. fistula</italic> plant has plenty of medicinal values.
It has been reported to have antibacterial, antifungal, antiviral,
and antioxidant activities.<sup><xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> It has been used to
treat tuberculosis, rheumatism, leprosy, syphilis, and skin disease.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> There has been an exponential growth in the
study of primary and secondary metabolite compositions of <italic>C. fistula</italic> in the last few years, which are responsible
for most of its attributed biological effects.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> There are around 12 glycosylated phenolic compounds (including
one lignan, two phenolic acids, and nine flavonoids) reported in its
leaf extract yet (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). These phytochemicals were selected for <italic>in silico</italic> docking study against unique drug targets of <italic>L. donovani</italic>. Proanthocyanidin B dimer, kaempferol rhamnosylxyloside, myricetin
hexoside, apigenin-6,8-di-<italic>C</italic>-glycoside, apigenin-C-hexoside-O-pentoside,
and 3,4-di-O-caffeoylquinic acid showed binding affinity toward the
drug targets of <italic>L. donovani</italic>. Proanthocyanidin
B dimer and kaempferol rhamnosylxyloside showed the highest binding
affinity toward <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1. The predicted inhibition
constants of proanthocyanidin B dimer against <italic>Ld</italic>SMT, <italic>Ld</italic>TR, <italic>Ld</italic>NH, and <italic>Ld</italic>PTR1
are calculated as 6.92 &#x003bc;M, 6.18 &#x003bc;M, 5.74 &#x003bc;M, and
5.00 &#x003bc;M respectively (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Molecular docking results suggested possible antileishmanial
activity of <italic>C. fistula</italic>. In the light
of <italic>in silico</italic> results and medicinal values including
antimicrobial activities, we further evaluated its leishmanicidal
activities <italic>in vitro</italic>. Methanolic extract of <italic>C. fistula</italic> leaves was found effective on promastigotes
as well as intramacrophagic amastigote forms in a dose-dependent manner.
Leaf extract was found very much safe against human THP-1-derived
macrophages with a very high CC<sub>50</sub> value of 626 &#x000b1; 39
&#x003bc;g/mL. Although the positive control, an existing antileishmanial
drug, miltefosine was found relatively more toxic on human macrophages
as reported by others as well as by us (CC<sub>50</sub> = 7.133 &#x000b1;
0.65 &#x003bc;g/mL). The exact mechanism of the antileishmanial activity
of <italic>C. fistula</italic> extract was not dissected
in detail, but our apoptotic assay suggested partial induction of
apoptosis in parasites upon treatment. The number of dead parasites
and the percentage of apoptotic cells are not correlated, which suggested
the other possible mechanism of antileishmanial activity of the extract.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Phytochemicals Reported in <italic>C. fistula</italic> Leaf Extract<sup><xref ref-type="bibr" rid="ref15">15</xref></sup></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">s. no.</th><th style="border:none;" align="center">phytochemicals</th><th style="border:none;" align="center">molecular formula</th><th style="border:none;" align="center">class
of compound</th></tr></thead><tbody><tr><td style="border:none;" align="left">1</td><td style="border:none;" align="left">syringaresinol</td><td style="border:none;" align="left">C<sub>22</sub>H<sub>26</sub>O<sub>8</sub></td><td style="border:none;" align="left">lignan</td></tr><tr><td style="border:none;" align="left">2</td><td style="border:none;" align="left">quercetin-<italic>O</italic>-hexoside</td><td style="border:none;" align="left">C<sub>21</sub>H<sub>20</sub>O<sub>12</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">3</td><td style="border:none;" align="left">apigenin-6,8-di-<italic>C</italic>-glycoside</td><td style="border:none;" align="left">C<sub>27</sub>H<sub>30</sub>O<sub>15</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">4</td><td style="border:none;" align="left">kaempferol rhamnosylxyloside</td><td style="border:none;" align="left">C<sub>26</sub>H<sub>28</sub>O<sub>14</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">5</td><td style="border:none;" align="left">coumaric acid derivative</td><td style="border:none;" align="left">-</td><td style="border:none;" align="left">phenolic acid</td></tr><tr><td style="border:none;" align="left">6</td><td style="border:none;" align="left">apigenin-6-<italic>C</italic>-pentoside-8-<italic>C</italic>-hexoside&#x000a0;(isomer&#x000a0;1)</td><td style="border:none;" align="left">C<sub>26</sub>H<sub>28</sub>O<sub>14</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">7</td><td style="border:none;" align="left">apigenin-6-<italic>C</italic>-pentoside-8-<italic>C</italic>-hexoside&#x000a0;(isomer&#x000a0;2)</td><td style="border:none;" align="left">C<sub>26</sub>H<sub>28</sub>O<sub>14</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">8</td><td style="border:none;" align="left">apigenin-6-<italic>C</italic>-pentoside-8-<italic>C</italic>-hexoside&#x000a0;(isomer&#x000a0;3)</td><td style="border:none;" align="left">C<sub>26</sub>H<sub>28</sub>O<sub>14</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">9</td><td style="border:none;" align="left">apigenin-<italic>C</italic>-hexoside-<italic>O</italic>-pentoside</td><td style="border:none;" align="left">C<sub>26</sub>H<sub>28</sub>O<sub>14</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">10</td><td style="border:none;" align="left">myricetin hexoside</td><td style="border:none;" align="left">C<sub>21</sub>H<sub>20</sub>O<sub>13</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">11</td><td style="border:none;" align="left">proanthocyanidin B dimer</td><td style="border:none;" align="left">C<sub>30</sub>H<sub>26</sub>O<sub>12</sub></td><td style="border:none;" align="left">flavonoid</td></tr><tr><td style="border:none;" align="left">12</td><td style="border:none;" align="left">3,4-di-<italic>O</italic>-caffeoylquinic&#x000a0;acid</td><td style="border:none;" align="left">C<sub>25</sub>H<sub>24</sub>O<sub>12</sub></td><td style="border:none;" align="left">phenolic acid</td></tr></tbody></table></table-wrap></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p>The <italic>in silico</italic> data suggested that phytoconstituents
possibly inhibited the key drug targets of <italic>L. donovani</italic>, which are important for their growth and survival. Further detailed
studies are required to work out the exact mechanism of antileishmanial
action of the <italic>C. fistula</italic> leaf extract <italic>in vitro</italic> as well as <italic>in vivo</italic>. Our findings
may be helpful for designing of the treatment of leishmaniasis through
the use of <italic>C. fistula</italic> alone or in combination
with the existing antileishmanial drugs.</p></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.0c05629?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.0c05629</ext-link>.<list id="silist" list-type="simple"><list-item><p>Three-dimensional cartoons
and topology maps of <italic>Ld</italic>SMT, <italic>Ld</italic>TR,
and <italic>Ld</italic>NH,
and template structures used for homology modeling of target proteins
of <italic>L. donovani</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c05629/suppl_file/ao0c05629_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao0c05629_si_001.pdf"><caption><p>ao0c05629_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="funding-statement" id="notes-2"><p>The authors
thank the Deanship of Scientific Research at Majmaah University, Al
Majmaah, 11952, Saudi Arabia, for supporting this work under the Group
Project Number RGP-2019-31. The authors are also thankful to the Ministry
of Ayush for funding (Z.28015/252/2016-HPC (EMR)-AYUSH-C).</p></notes><notes notes-type="COI-statement" id="NOTES-d7e1971-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors are thankful to the Central Instrumentation Facility,
Jamia Millia Islamia, for support.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bates</surname><given-names>P. A.</given-names></name>
<article-title>Revising
Leishmania&#x02019;s life cycle</article-title>. <source>Nat. Microbiol.</source>
<year>2018</year>, <volume>3</volume>, <fpage>529</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-018-0154-2</pub-id>.<pub-id pub-id-type="pmid">29693656</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Walters</surname><given-names>L. L.</given-names></name>; <name><surname>Irons</surname><given-names>K. P.</given-names></name>; <name><surname>Chaplin</surname><given-names>G.</given-names></name>; <name><surname>Tesh</surname><given-names>R. B.</given-names></name>
<article-title>Life cycle of Leishmania
major (Kinetoplastida: Trypanosomatidae) in the neotropical sand fly
Lutzomyia longipalpis (Diptera: Psychodidae)</article-title>. <source>J. Med. Entomol.</source>
<year>1993</year>, <volume>30</volume>, <fpage>699</fpage>&#x02013;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1093/jmedent/30.4.699</pub-id>.<pub-id pub-id-type="pmid">8360894</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Alvar</surname><given-names>J.</given-names></name>; <name><surname>V&#x000e9;lez</surname><given-names>I. D.</given-names></name>; <name><surname>Bern</surname><given-names>C.</given-names></name>; <name><surname>Herrero</surname><given-names>M.</given-names></name>; <name><surname>Desjeux</surname><given-names>P.</given-names></name>; <name><surname>Cano</surname><given-names>J.</given-names></name>; <name><surname>Jannin</surname><given-names>J.</given-names></name>; <name><surname>den Boer</surname><given-names>M.</given-names></name>
<article-title>Leishmaniasis worldwide
and global estimates of its incidence</article-title>. <source>PLoS
One</source>
<year>2012</year>, <volume>7</volume>, <elocation-id>e35671</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035671</pub-id>.<pub-id pub-id-type="pmid">22693548</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="book" id="cit4"><person-group person-group-type="allauthors"><name><surname>Searo</surname><given-names>W.</given-names></name></person-group><source>Regional Strategic Framework
for Elimination of Kala-azar from South-East Asia Region (2005&#x02013;2015)</source>; <publisher-name>World Health Organization, Regional Office for
South-East Asia</publisher-name>: <publisher-loc>New Delhi, India</publisher-loc>, <year>2005</year>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apps.searo.who.int/pds_docs/B0211.pdf">http://apps.searo.who.int/pds_docs/B0211.pdf</uri>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Sundar</surname><given-names>S.</given-names></name>; <name><surname>Singh</surname><given-names>A.</given-names></name>; <name><surname>Rai</surname><given-names>M.</given-names></name>; <name><surname>Prajapati</surname><given-names>V. K.</given-names></name>; <name><surname>Singh</surname><given-names>A. K.</given-names></name>; <name><surname>Ostyn</surname><given-names>B.</given-names></name>; <name><surname>Boelaert</surname><given-names>M.</given-names></name>; <name><surname>Dujardin</surname><given-names>J. C.</given-names></name>; <name><surname>Chakravarty</surname><given-names>J.</given-names></name>
<article-title>Efficacy of miltefosine in the treatment
of visceral
leishmaniasis in India after a decade of use</article-title>. <source>Clin. Infect. Dis.</source>
<year>2012</year>, <volume>55</volume>, <fpage>543</fpage>&#x02013;<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cis474</pub-id>.<pub-id pub-id-type="pmid">22573856</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Burza</surname><given-names>S.</given-names></name>; <name><surname>Sinha</surname><given-names>P. K.</given-names></name>; <name><surname>Mahajan</surname><given-names>R.</given-names></name>; <name><surname>Lima</surname><given-names>M. A.</given-names></name>; <name><surname>Mitra</surname><given-names>G.</given-names></name>; <name><surname>Verma</surname><given-names>N.</given-names></name>; <name><surname>Balasegaram</surname><given-names>M.</given-names></name>; <name><surname>Das</surname><given-names>P.</given-names></name>
<article-title>Risk factors for visceral
leishmaniasis relapse in immunocompetent patients following treatment
with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India</article-title>. <source>PLoS Neglected Trop. Dis.</source>
<year>2014</year>, <volume>8</volume>, <elocation-id>e2536</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002536</pub-id>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Ouakad</surname><given-names>M.</given-names></name>; <name><surname>Vanaerschot</surname><given-names>M.</given-names></name>; <name><surname>Rijal</surname><given-names>S.</given-names></name>; <name><surname>Sundar</surname><given-names>S.</given-names></name>; <name><surname>Speybroeck</surname><given-names>N.</given-names></name>; <name><surname>Kestens</surname><given-names>L.</given-names></name>; <name><surname>Boel</surname><given-names>L.</given-names></name>; <name><surname>De Doncker</surname><given-names>S.</given-names></name>; <name><surname>Maes</surname><given-names>I.</given-names></name>; <name><surname>Decuypere</surname><given-names>S.</given-names></name>; <name><surname>Dujardin</surname><given-names>J. C.</given-names></name>
<article-title>Increased metacyclogenesis
of antimony-resistant <italic>Leishmania donovani</italic> clinical lines</article-title>. <source>Parasitology</source>
<year>2011</year>, <volume>138</volume>, <fpage>1392</fpage>&#x02013;<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1017/S0031182011001120</pub-id>.<pub-id pub-id-type="pmid">21819638</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Rahmani</surname><given-names>A. H.</given-names></name>
<article-title><italic>Cassia fistula</italic> Linn: Potential candidate in the health
management</article-title>. <source>Pharmacogn. Res.</source>
<year>2015</year>, <volume>7</volume>, <fpage>217</fpage>&#x02013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.4103/0974-8490.157956</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Yadav</surname><given-names>R.</given-names></name>; <name><surname>Jain</surname><given-names>G. C.</given-names></name>
<article-title>Antifertility effect of aqueous extract
of seeds of <italic>Cassia fistula</italic> in female
rats</article-title>. <source>Adv. contracept.</source>
<year>1999</year>, <volume>15</volume>, <fpage>293</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1023/A:1006784224191</pub-id>.<pub-id pub-id-type="pmid">11145371</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Panda</surname><given-names>S. K.</given-names></name>; <name><surname>Padhi</surname><given-names>L. P.</given-names></name>; <name><surname>Mohanty</surname><given-names>G.</given-names></name>
<article-title>Antibacterial activities and phytochemical
analysis of <italic>Cassia fistula</italic> (Linn.)
leaf</article-title>. <source>J. Adv. Pharm. Technol. Res.</source>
<year>2011</year>, <volume>2</volume>, <fpage>62</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.4103/2231-4040.79814</pub-id>.<pub-id pub-id-type="pmid">22171295</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Vasudevan</surname><given-names>D. T.</given-names></name>; <name><surname>Dinesh</surname><given-names>K. R.</given-names></name>; <name><surname>Gopalakrishnan</surname><given-names>S.</given-names></name>; <name><surname>Sreekanth</surname><given-names>S.</given-names></name>; <name><surname>Sonal</surname><given-names>S.</given-names></name>
<article-title>The potential of aqueous and isolated fraction from leaves of <italic>Cassia fistula</italic> Linn as antibacterial agent</article-title>. <source>Int. J. Chem. Sci.</source>
<year>2009</year>, <volume>7</volume>, <fpage>2363</fpage>&#x02013;<lpage>2367</lpage>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Kumar</surname><given-names>K.</given-names></name>; <name><surname>Satish</surname><given-names>S.</given-names></name>; <name><surname>Sayeed</surname><given-names>I.</given-names></name>; <name><surname>Hedge</surname><given-names>K.</given-names></name>
<article-title>Therapeutic Uses of <italic>Cassia fistula</italic>: Review</article-title>. <source>Int.
J. Pharm. Chem. Res.</source>
<year>2017</year>, <volume>3</volume>, <fpage>38</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Thirumal</surname><given-names>M.</given-names></name>; <name><surname>Srimanthula</surname><given-names>S.</given-names></name>; <name><surname>Kishore</surname><given-names>G.</given-names></name>
<article-title><italic>Cassia fistula</italic> Linn-Pharmacognostical, phytochemical and pharmacological review</article-title>. <source>Crit. Rev. Pharm. Sci.</source>
<year>2012</year>, <volume>1</volume>, <fpage>43</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Senthil
Kumar</surname><given-names>M.</given-names></name>; <name><surname>Sripriya</surname><given-names>R.</given-names></name>; <name><surname>Vijaya Raghavan</surname><given-names>H.</given-names></name>; <name><surname>Sehgal</surname><given-names>P. K.</given-names></name>
<article-title>Wound healing potential of <italic>Cassia fistula</italic> on infected albino rat model</article-title>. <source>J. Surg. Res.</source>
<year>2006</year>, <volume>131</volume>, <fpage>283</fpage>&#x02013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2005.08.025</pub-id>.<pub-id pub-id-type="pmid">16242721</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Castro-Lopez</surname><given-names>C.</given-names></name>; <name><surname>Rojas</surname><given-names>R.</given-names></name>; <name><surname>Mart&#x000ed;nez-Avila</surname><given-names>G.</given-names></name>
<article-title>Screening
of the <italic>Cassia fistula</italic> Phytochemical
Constituents by UPLC-ESI-QTOF-MS2</article-title>. <source>Clin. Oncol.</source>
<year>2018</year>, <volume>3</volume>, <fpage>1477</fpage>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Pei</surname><given-names>K.</given-names></name>; <name><surname>Ou</surname><given-names>J.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Ou</surname><given-names>S.</given-names></name>
<article-title>p-Coumaric acid and
its conjugates:
dietary sources, pharmacokinetic properties and biological activities</article-title>. <source>J. Sci. Food Agric.</source>
<year>2016</year>, <volume>96</volume>, <fpage>2952</fpage>&#x02013;<lpage>2962</lpage>. <pub-id pub-id-type="doi">10.1002/jsfa.7578</pub-id>.<pub-id pub-id-type="pmid">26692250</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Monzote</surname><given-names>L.</given-names></name>; <name><surname>C&#x000f3;rdova</surname><given-names>W. H. P.</given-names></name>; <name><surname>Garc&#x000ed;a</surname><given-names>M.</given-names></name>; <name><surname>Pi&#x000f1;&#x000f3;n</surname><given-names>A.</given-names></name>; <name><surname>Setzer</surname><given-names>W. N.</given-names></name>
<article-title>In-vitro and In-vivo Activities of Phenolic Compounds
A gainst Cutaneous Leishmaniasis</article-title>. <source>Rec. Nat.
Prod.</source>
<year>2016</year>, <volume>10</volume>, <fpage>269</fpage>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Costa</surname><given-names>R. S.</given-names></name>; <name><surname>Souza Filho</surname><given-names>O. P.</given-names></name>; <name><surname>Dias J&#x000fa;nior</surname><given-names>O.</given-names></name>; <name><surname>Silva</surname><given-names>J. J.</given-names></name>; <name><surname>Hyaric</surname><given-names>M. L.</given-names></name>; <name><surname>Santos</surname><given-names>M. A.</given-names></name>; <name><surname>Velozo</surname><given-names>E. S.</given-names></name>
<article-title>In vitro antileishmanial and antitrypanosomal
activity of compounds isolated from the roots of Zanthoxylum tingoassuiba</article-title>. <source>Rev. Bras. Farmacogn.</source>
<year>2018</year>, <volume>28</volume>, <fpage>551</fpage>&#x02013;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjp.2018.04.013</pub-id>.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Semwal</surname><given-names>D. K.</given-names></name>; <name><surname>Semwal</surname><given-names>R. B.</given-names></name>; <name><surname>Combrinck</surname><given-names>S.</given-names></name>; <name><surname>Viljoen</surname><given-names>A.</given-names></name>
<article-title>Myricetin: A Dietary
Molecule with Diverse Biological Activities</article-title>. <source>Nutrients</source>
<year>2016</year>, <volume>8</volume>, <fpage>90</fpage><pub-id pub-id-type="doi">10.3390/nu8020090</pub-id>.<pub-id pub-id-type="pmid">26891321</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Kubata</surname><given-names>B. K.</given-names></name>; <name><surname>Nagamune</surname><given-names>K.</given-names></name>; <name><surname>Murakami</surname><given-names>N.</given-names></name>; <name><surname>Merkel</surname><given-names>P.</given-names></name>; <name><surname>Kabututu</surname><given-names>Z.</given-names></name>; <name><surname>Martin</surname><given-names>S. K.</given-names></name>; <name><surname>Kalulu</surname><given-names>T. M.</given-names></name>; <name><surname>Huq</surname><given-names>M.</given-names></name>; <name><surname>Yoshida</surname><given-names>M.</given-names></name>; <name><surname>Ohnishi-Kameyama</surname><given-names>M.</given-names></name>; <name><surname>Kinoshita</surname><given-names>T.</given-names></name>; <name><surname>Duszenko</surname><given-names>M.</given-names></name>; <name><surname>Urade</surname><given-names>Y.</given-names></name>
<article-title>Kola acuminata
proanthocyanidins: a class of anti-trypanosomal compounds effective
against Trypanosoma brucei</article-title>. <source>Int. J. Parasitol.</source>
<year>2005</year>, <volume>35</volume>, <fpage>91</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpara.2004.10.019</pub-id>.<pub-id pub-id-type="pmid">15619520</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Cheuka</surname><given-names>P. M.</given-names></name>; <name><surname>Mayoka</surname><given-names>G.</given-names></name>; <name><surname>Mutai</surname><given-names>P.</given-names></name>; <name><surname>Chibale</surname><given-names>K.</given-names></name>
<article-title>The Role of Natural
Products in Drug Discovery and Development against Neglected Tropical
Diseases</article-title>. <source>Molecules</source>
<year>2016</year>, <volume>22</volume>, <elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22010058</pub-id>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Verma</surname><given-names>S. S.</given-names></name>; <name><surname>Dwivedi</surname><given-names>N.</given-names></name>; <name><surname>Singh</surname><given-names>N.</given-names></name>; <name><surname>Siddiqi</surname><given-names>M. I.</given-names></name>; <name><surname>Tripathi</surname><given-names>R. P.</given-names></name>; <name><surname>Dube</surname><given-names>A.</given-names></name>; <name><surname>Singh</surname><given-names>N.</given-names></name>
<article-title><italic>Leishmania donovani</italic> pteridine reductase
1: biochemical
properties and structure-modeling studies</article-title>. <source>Exp.
Parasitol.</source>
<year>2008</year>, <volume>120</volume>, <fpage>73</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.exppara.2008.05.005</pub-id>.<pub-id pub-id-type="pmid">18617167</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Baiocco</surname><given-names>P.</given-names></name>; <name><surname>Colotti</surname><given-names>G.</given-names></name>; <name><surname>Franceschini</surname><given-names>S.</given-names></name>; <name><surname>Ilari</surname><given-names>A.</given-names></name>
<article-title>Molecular basis of
antimony treatment in leishmaniasis</article-title>. <source>J. Med.
Chem.</source>
<year>2009</year>, <volume>52</volume>, <fpage>2603</fpage>&#x02013;<lpage>2612</lpage>. <pub-id pub-id-type="doi">10.1021/jm900185q</pub-id>.<pub-id pub-id-type="pmid">19317451</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Mukherjee</surname><given-names>S.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>; <name><surname>Hsu</surname><given-names>F. F.</given-names></name>; <name><surname>Patel</surname><given-names>J.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>K.</given-names></name>
<article-title>Sterol methyltransferase
is required for optimal mitochondrial function and virulence in Leishmania
major</article-title>. <source>Mol. Microbiol.</source>
<year>2019</year>, <volume>111</volume>, <fpage>65</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/mmi.14139</pub-id>.<pub-id pub-id-type="pmid">30260041</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Goto</surname><given-names>Y.</given-names></name>; <name><surname>Bhatia</surname><given-names>A.</given-names></name>; <name><surname>Raman</surname><given-names>V. S.</given-names></name>; <name><surname>Vidal</surname><given-names>S. E.</given-names></name>; <name><surname>Bertholet</surname><given-names>S.</given-names></name>; <name><surname>Coler</surname><given-names>R. N.</given-names></name>; <name><surname>Howard</surname><given-names>R. F.</given-names></name>; <name><surname>Reed</surname><given-names>S. G.</given-names></name>
<article-title>Leishmania infantum
sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection
against L. major infection</article-title>. <source>Vaccine</source>
<year>2009</year>, <volume>27</volume>, <fpage>2884</fpage>&#x02013;<lpage>2890</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.079</pub-id>.<pub-id pub-id-type="pmid">19428898</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Nico</surname><given-names>D.</given-names></name>; <name><surname>Gomes</surname><given-names>D. C.</given-names></name>; <name><surname>Palatnik-de-Sousa</surname><given-names>I.</given-names></name>; <name><surname>Morrot</surname><given-names>A.</given-names></name>; <name><surname>Palatnik</surname><given-names>M.</given-names></name>; <name><surname>Palatnik-de-Sousa</surname><given-names>C. B.</given-names></name>
<article-title><italic>Leishmania donovani</italic> Nucleoside
Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against
Leishmania amazonensis Murine Infection</article-title>. <source>Front.
Immunol.</source>
<year>2014</year>, <volume>5</volume>, <fpage>273</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00273</pub-id>.<pub-id pub-id-type="pmid">24966857</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Dallakyan</surname><given-names>S.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>Small-molecule library screening
by docking with PyRx</article-title>. <source>Methods Mol. Biol.</source>
<year>2015</year>, <volume>1263</volume>, <fpage>243</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">25618350</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Trott</surname><given-names>O.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>AutoDock Vina: improving
the speed and accuracy of
docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J. Comput. Chem.</source>
<year>2010</year>, <volume>31</volume>, <fpage>455</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Shamsi</surname><given-names>A.</given-names></name>; <name><surname>Mohammad</surname><given-names>T.</given-names></name>; <name><surname>Anwar</surname><given-names>S.</given-names></name>; <name><surname>AlAjmi</surname><given-names>M. F.</given-names></name>; <name><surname>Hussain</surname><given-names>A.</given-names></name>; <name><surname>Rehman</surname><given-names>M. T.</given-names></name>; <name><surname>Islam</surname><given-names>A.</given-names></name>; <name><surname>Hassan</surname><given-names>M. I.</given-names></name>
<article-title>Glecaprevir and
Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease:
possible implication in COVID-19 therapy</article-title>. <source>Biosci.
Rep.</source>
<year>2020</year>, <volume>40</volume>, <elocation-id>450</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20201256</pub-id>.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Kashif</surname><given-names>M.</given-names></name>; <name><surname>Hira</surname><given-names>S. K.</given-names></name>; <name><surname>Upadhyaya</surname><given-names>A.</given-names></name>; <name><surname>Gupta</surname><given-names>U.</given-names></name>; <name><surname>Singh</surname><given-names>R.</given-names></name>; <name><surname>Paladhi</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>F. I.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>; <name><surname>Manna</surname><given-names>P. P.</given-names></name>
<article-title>In silico
studies and evaluation of antiparasitic role of a novel pyruvate phosphate
dikinase inhibitor in <italic>Leishmania donovani</italic> infected macrophages</article-title>. <source>Int. J. Antimicrob.
Agents</source>
<year>2019</year>, <volume>53</volume>, <fpage>508</fpage>&#x02013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.12.011</pub-id>.<pub-id pub-id-type="pmid">30599242</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>&#x00160;ali</surname><given-names>A.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>
<article-title>Comparative protein
modelling by satisfaction of spatial
restraints</article-title>. <source>J. Mol. Biol.</source>
<year>1993</year>, <volume>234</volume>, <fpage>779</fpage>&#x02013;<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1993.1626</pub-id>.<pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Laskowski</surname><given-names>R. A.</given-names></name>; <name><surname>Rullmannn</surname><given-names>J. A.</given-names></name>; <name><surname>MacArthur</surname><given-names>M. W.</given-names></name>; <name><surname>Kaptein</surname><given-names>R.</given-names></name>; <name><surname>Thornton</surname><given-names>J. M.</given-names></name>
<article-title>AQUA and
PROCHECK-NMR: programs for checking the quality of protein structures
solved by NMR</article-title>. <source>J. Biomol. NMR</source>
<year>1996</year>, <volume>8</volume>, <fpage>477</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1007/BF00228148</pub-id>.<pub-id pub-id-type="pmid">9008363</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Laskowski</surname><given-names>R. A.</given-names></name>
<article-title>PDBsum
new things</article-title>. <source>Nucleic Acids Res.</source>
<year>2009</year>, <volume>37</volume>, <fpage>D355</fpage>&#x02013;<lpage>D359</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn860</pub-id>.<pub-id pub-id-type="pmid">18996896</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Kashif</surname><given-names>M.</given-names></name>; <name><surname>Tabrez</surname><given-names>S.</given-names></name>; <name><surname>Husein</surname><given-names>A.</given-names></name>; <name><surname>Arish</surname><given-names>M.</given-names></name>; <name><surname>Kalaiarasan</surname><given-names>P.</given-names></name>; <name><surname>Manna</surname><given-names>P. P.</given-names></name>; <name><surname>Subbarao</surname><given-names>N.</given-names></name>; <name><surname>Akhter</surname><given-names>Y.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>
<article-title>Identification
of novel inhibitors against UDP-galactopyranose mutase to combat leishmaniasis</article-title>. <source>J. Cell. Biochem.</source>
<year>2018</year>, <volume>119</volume>, <fpage>2653</fpage>&#x02013;<lpage>2665</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.26433</pub-id>.<pub-id pub-id-type="pmid">29058760</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>O&#x02019;Boyle</surname><given-names>N. M.</given-names></name>; <name><surname>Banck</surname><given-names>M.</given-names></name>; <name><surname>James</surname><given-names>C. A.</given-names></name>; <name><surname>Morley</surname><given-names>C.</given-names></name>; <name><surname>Vandermeersch</surname><given-names>T.</given-names></name>; <name><surname>Hutchison</surname><given-names>G. R.</given-names></name>
<article-title>Open Babel: An open chemical toolbox</article-title>. <source>J. Cheminf.</source>
<year>2011</year>, <volume>3</volume>, <fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Rapp&#x000e9;</surname><given-names>A. K.</given-names></name>; <name><surname>Casewit</surname><given-names>C. J.</given-names></name>; <name><surname>Colwell</surname><given-names>K.</given-names></name>; <name><surname>Goddard</surname><given-names>W. A.</given-names><suffix>III</suffix></name>; <name><surname>Skiff</surname><given-names>W. M.</given-names></name>
<article-title>UFF, a full periodic
table force field for molecular
mechanics and molecular dynamics simulations</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1992</year>, <volume>114</volume>, <fpage>10024</fpage>&#x02013;<lpage>10035</lpage>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Raj</surname><given-names>S.</given-names></name>; <name><surname>Sasidharan</surname><given-names>S.</given-names></name>; <name><surname>Dubey</surname><given-names>V. K.</given-names></name>; <name><surname>Saudagar</surname><given-names>P.</given-names></name>
<article-title>Identification of lead
molecules against potential drug target protein MAPK4 from <italic>L. donovani</italic>: An in-silico approach using docking,
molecular dynamics and binding free energy calculation</article-title>. <source>PLoS One</source>
<year>2019</year>, <volume>14</volume>, <elocation-id>e0221331</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0221331</pub-id>.<pub-id pub-id-type="pmid">31425543</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Wadood</surname><given-names>A.</given-names></name>; <name><surname>Ahmed</surname><given-names>N.</given-names></name>; <name><surname>Shah</surname><given-names>L.</given-names></name>; <name><surname>Ahmad</surname><given-names>A.</given-names></name>; <name><surname>Hassan</surname><given-names>H.</given-names></name>; <name><surname>Shams</surname><given-names>S.</given-names></name>
<article-title>In-silico drug design: An approach which revolutionarised the drug
discovery process</article-title>. <source>OA Drug Des. Delivery</source>
<year>2013</year>, <volume>1</volume>, <fpage>3</fpage><pub-id pub-id-type="doi">10.13172/2054-4057-1-1-1119</pub-id>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="conf-proc" id="cit39"><person-group person-group-type="allauthors"><name><surname>Farnsworth</surname><given-names>N. R.</given-names></name></person-group><article-title>The Role of Ethnopharmacology in Drug Development</article-title>. In <source>Ciba Foundation Symposium 154-Bioactive Compounds from
Plants: Bioactive Compounds from Plants</source>, Ciba Foundation
Symposium 154; <publisher-name>John Wiley &#x00026; Sons</publisher-name>: <publisher-loc>Chichester, U.K.</publisher-loc>, <year>1990</year>; pp <fpage>2</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Chouhan</surname><given-names>G.</given-names></name>; <name><surname>Islamuddin</surname><given-names>M.</given-names></name>; <name><surname>Sahal</surname><given-names>D.</given-names></name>; <name><surname>Afrin</surname><given-names>F.</given-names></name>
<article-title>Exploring the role
of medicinal plant-based immunomodulators for effective therapy of
leishmaniasis</article-title>. <source>Front. Immunol.</source>
<year>2014</year>, <volume>5</volume>, <fpage>193</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00193</pub-id>.<pub-id pub-id-type="pmid">24829566</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Tahir</surname><given-names>A. E.</given-names></name>; <name><surname>Ibrahim</surname><given-names>A. M.</given-names></name>; <name><surname>Satti</surname><given-names>G. M.</given-names></name>; <name><surname>Theander</surname><given-names>T. G.</given-names></name>; <name><surname>Kharazmi</surname><given-names>A.</given-names></name>; <name><surname>Khalid</surname><given-names>S. A.</given-names></name>
<article-title>The potential antileishmanial activity
of some Sudanese
medicinal plants</article-title>. <source>Phytother. Res.</source>
<year>1998</year>, <volume>12</volume>, <fpage>576</fpage>&#x02013;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1099-1573(199812)12:8&#x0003c;576::AID-PTR354&#x0003e;3.0.CO;2-#</pub-id>.</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="book" id="cit42"><person-group person-group-type="allauthors"><name><surname>Kirtikar</surname><given-names>K.</given-names></name>; <name><surname>Basu</surname><given-names>B.
D.</given-names></name></person-group><source>Indian Medicinal Plants</source>; <publisher-name>International Book Distributer</publisher-name>, <year>1918</year>; pp <fpage>1038</fpage>&#x02013;<lpage>1063</lpage>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="book" id="cit43"><person-group person-group-type="allauthors"><name><surname>Khan</surname><given-names>I.</given-names></name>; <name><surname>Khanum</surname><given-names>I.</given-names></name></person-group><source>Medicinal
and Aromatic
Plants of India</source>; <publisher-name>Ukkaz Publications</publisher-name>: <publisher-loc>Hyderabad</publisher-loc>, <year>2005</year>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Nagpal</surname><given-names>M. A.</given-names></name>; <name><surname>Nagpal</surname><given-names>N.</given-names></name>; <name><surname>Rahar</surname><given-names>S.</given-names></name>; <name><surname>Shah</surname><given-names>G.</given-names></name>; <name><surname>Swami</surname><given-names>G.</given-names></name>; <name><surname>Kapoor</surname><given-names>R.</given-names></name>
<article-title>Phytochemical investigation of methanolic
extract of <italic>Cassia fistula</italic> leaves</article-title>. <source>Pharmacogn.
J.</source>
<year>2011</year>, <volume>3</volume>, <fpage>61</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.5530/pj.2011.26.11</pub-id>.</mixed-citation></ref></ref-list></back></article>